# XTI Aerospace, Inc.: financial statements, quarterly

XTIA · Nasdaq · CIK 1529113 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xtia.md) · [Financials](/companies/xtia/financials.md) · [Filings](/companies/xtia/filings.md) · [Insiders](/companies/xtia/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xtia/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001628280-24-047969.md) | [4.6 d](/filings/0001628280-24-016449.md) | [0.2](/filings/0001628280-24-024396.md) | [1.0](/filings/0001628280-24-037277.md) | [0.9](/filings/0001628280-24-047969.md) | [1.0 d](/filings/0001213900-25-032213.md) | [0.5](/filings/0001213900-25-045396.md) | [0.0](/filings/0001628280-26-066538.md) | [2.5](/filings/0001213900-25-112615.md) | [18.9 d](/filings/0001213900-26-043785.md) | [27.7](/filings/0001213900-26-056270.md) | [32.4](/filings/0001628280-26-066538.md) |
| Cost of revenue | $m | [0.0](/filings/0001628280-24-047969.md) | [1.5 d](/filings/0001628280-24-016449.md) | [0.1](/filings/0001213900-25-045396.md) | [0.4](/filings/0001213900-25-076767.md) | [0.4](/filings/0001213900-25-112615.md) | [0.5 d](/filings/0001213900-25-032213.md) | [0.1](/filings/0001213900-25-045396.md) | [0.0](/filings/0001628280-26-066538.md) | [1.4](/filings/0001213900-25-112615.md) | [15.9 d](/filings/0001213900-26-043785.md) | [22.6](/filings/0001213900-26-056270.md) | [26.8](/filings/0001628280-26-066538.md) |
| Gross profit | $m | [0.0](/filings/0001628280-24-047969.md) | [3.1 d](/filings/0001628280-24-016449.md) | [0.1](/filings/0001213900-25-045396.md) | [0.7](/filings/0001213900-25-076767.md) | [0.5](/filings/0001213900-25-112615.md) | [0.6 d](/filings/0001213900-25-032213.md) | [0.3](/filings/0001213900-25-045396.md) | [0.0](/filings/0001628280-26-066538.md) | [1.1](/filings/0001213900-25-112615.md) | [3.0 d](/filings/0001213900-26-043785.md) | [5.1](/filings/0001213900-26-056270.md) | [5.6](/filings/0001628280-26-066538.md) |
| Research and development | $m | [0.5](/filings/0001628280-24-047969.md) | [0.1 d](/filings/0001213900-25-032213.md) | [0.5](/filings/0001213900-25-045396.md) | [1.1](/filings/0001213900-25-076767.md) | [1.2](/filings/0001213900-25-112615.md) | [(0.9) d](/filings/0001213900-26-043785.md) | [1.1](/filings/0001213900-26-056270.md) | [1.4](/filings/0001628280-26-066538.md) | [2.0](/filings/0001213900-25-112615.md) | [(0.4) d](/filings/0001213900-26-043785.md) | [1.2](/filings/0001213900-26-056270.md) | [0.6](/filings/0001628280-26-066538.md) |
| Operating income | $m | [(2.4)](/filings/0001628280-24-047969.md) | [0.1 d](/filings/0001213900-25-032213.md) | [(8.9)](/filings/0001213900-25-045396.md) | [(13.9)](/filings/0001213900-25-076767.md) | [(4.2)](/filings/0001213900-25-112615.md) | [(2.6) d](/filings/0001213900-26-043785.md) | [(8.2)](/filings/0001213900-26-056270.md) | [(5.8)](/filings/0001628280-26-066538.md) | [(14.8)](/filings/0001213900-25-112615.md) | [(6.5) d](/filings/0001213900-26-043785.md) | [(10.4)](/filings/0001213900-26-056270.md) | [(9.1)](/filings/0001628280-26-066538.md) |
| Interest expense | $m | not reported | not reported | [0.3](/filings/0001213900-25-045396.md) | [0.1](/filings/0001213900-25-076767.md) | [0.2](/filings/0001213900-25-112615.md) | [0.2 d](/filings/0001213900-26-043785.md) | [0.2](/filings/0001213900-26-056270.md) | [0.0](/filings/0001628280-26-066538.md) | [0.0](/filings/0001213900-25-112615.md) | [0.1 d](/filings/0001213900-26-043785.md) | [0.2](/filings/0001213900-26-056270.md) | [0.1](/filings/0001628280-26-066538.md) |
| Income tax | $m | [0.0](/filings/0001628280-24-047969.md) | [0.0 d](/filings/0001628280-24-016449.md) | [0.0](/filings/0001213900-25-045396.md) | [0.0](/filings/0001213900-25-076767.md) | [0.0](/filings/0001628280-24-047969.md) | [0.0 d](/filings/0001213900-26-043785.md) | [(0.0)](/filings/0001213900-26-056270.md) | [0.0](/filings/0001628280-26-066538.md) | [0.0](/filings/0001213900-25-112615.md) | [(0.0) d](/filings/0001213900-26-043785.md) | not reported | [0.0](/filings/0001628280-26-066538.md) |
| Net income | $m | [(2.7)](/filings/0001628280-24-047969.md) | [(16.2) d](/filings/0001213900-25-032213.md) | [(2.6)](/filings/0001213900-25-112615.md) | [(14.7)](/filings/0001213900-25-112615.md) | [(4.4)](/filings/0001213900-25-112615.md) | [(13.9) d](/filings/0001213900-26-043785.md) | [(12.9)](/filings/0001628280-26-066538.md) | [(20.9)](/filings/0001628280-26-066538.md) | [(13.4)](/filings/0001213900-25-112615.md) | [(21.6) d](/filings/0001213900-26-043785.md) | [(35.3)](/filings/0001628280-26-066538.md) | [(2.8)](/filings/0001628280-26-066538.md) |
| Diluted EPS | $ per share | [(0.66)](/filings/0001628280-24-047969.md) | not reported | [(124.05)](/filings/0001213900-25-045396.md) | [(261.99)](/filings/0001213900-25-076767.md) | [(33.40)](/filings/0001213900-25-112615.md) | not reported | [(3.80)](/filings/0001213900-26-056270.md) | [(2.93)](/filings/0001628280-26-066538.md) | [(0.61)](/filings/0001213900-25-112615.md) | not reported | [(1.00)](/filings/0001213900-26-056270.md) | [(0.07)](/filings/0001628280-26-066538.md) |
| Basic EPS | $ per share | [(0.66)](/filings/0001628280-24-047969.md) | not reported | [(124.05)](/filings/0001213900-25-045396.md) | [(261.99)](/filings/0001213900-25-076767.md) | [(33.40)](/filings/0001213900-25-112615.md) | not reported | [(3.80)](/filings/0001213900-26-056270.md) | [(2.93)](/filings/0001628280-26-066538.md) | [(0.61)](/filings/0001213900-25-112615.md) | not reported | [(1.00)](/filings/0001213900-26-056270.md) | [(0.07)](/filings/0001628280-26-066538.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [13.5](/filings/0001628280-23-039641.md) | [0.0](/filings/0001213900-25-032213.md) | [1.8](/filings/0001628280-24-024396.md) | [5.8](/filings/0001628280-24-037277.md) | [0.5](/filings/0001628280-24-047969.md) | [4.0](/filings/0001213900-26-043785.md) | [8.0](/filings/0001213900-25-045396.md) | [20.0](/filings/0001213900-25-076767.md) | [32.2](/filings/0001213900-25-112615.md) | [16.7](/filings/0001628280-26-066538.md) | [15.2](/filings/0001213900-26-056270.md) | [7.2](/filings/0001628280-26-066538.md) |
| Current assets | $m | [22.6](/filings/0001628280-23-039641.md) | [0.2](/filings/0001213900-25-032213.md) | [11.5](/filings/0001628280-24-024396.md) | [15.2](/filings/0001628280-24-037277.md) | [10.1](/filings/0001628280-24-047969.md) | [8.6](/filings/0001213900-26-043785.md) | [12.5](/filings/0001213900-25-045396.md) | [24.2](/filings/0001213900-25-076767.md) | [36.7](/filings/0001213900-25-112615.md) | [51.8](/filings/0001628280-26-066538.md) | [50.3](/filings/0001213900-26-056270.md) | [45.3](/filings/0001628280-26-066538.md) |
| Total assets | $m | [27.6](/filings/0001628280-23-039641.md) | [0.5](/filings/0001213900-25-032213.md) | [30.8](/filings/0001628280-24-024396.md) | [34.0](/filings/0001628280-24-037277.md) | [29.3](/filings/0001628280-24-047969.md) | [24.3](/filings/0001213900-26-043785.md) | [27.1](/filings/0001213900-25-045396.md) | [35.4](/filings/0001213900-25-076767.md) | [47.9](/filings/0001213900-25-112615.md) | [81.2](/filings/0001628280-26-066538.md) | [78.3](/filings/0001213900-26-056270.md) | [72.8](/filings/0001628280-26-066538.md) |
| Current liabilities | $m | [19.6](/filings/0001628280-23-039641.md) | [13.3](/filings/0001213900-25-032213.md) | [16.6](/filings/0001628280-24-024396.md) | [23.0](/filings/0001628280-24-037277.md) | [22.0](/filings/0001628280-24-047969.md) | [17.4](/filings/0001213900-26-043785.md) | [12.5](/filings/0001213900-25-045396.md) | [21.8](/filings/0001213900-25-076767.md) | [35.6](/filings/0001213900-25-112615.md) | [47.6](/filings/0001628280-26-066538.md) | [91.0](/filings/0001213900-26-056270.md) | [84.2](/filings/0001628280-26-066538.md) |
| Total liabilities | $m | [19.8](/filings/0001628280-23-039641.md) | [32.1](/filings/0001213900-25-032213.md) | [17.1](/filings/0001628280-24-024396.md) | [23.5](/filings/0001628280-24-037277.md) | [22.4](/filings/0001628280-24-047969.md) | [17.7](/filings/0001213900-26-043785.md) | [12.8](/filings/0001213900-25-045396.md) | [22.1](/filings/0001213900-25-076767.md) | [35.7](/filings/0001213900-25-112615.md) | [50.8](/filings/0001628280-26-066538.md) | [92.0](/filings/0001213900-26-056270.md) | [85.1](/filings/0001628280-26-066538.md) |
| Long-term debt | $m | not reported | [18.5](/filings/0001213900-25-032213.md) | [0.1](/filings/0001628280-24-024396.md) | [0.1](/filings/0001628280-24-037277.md) | [0.1](/filings/0001628280-24-047969.md) | [0.1](/filings/0001213900-26-043785.md) | [0.1](/filings/0001213900-25-045396.md) | [0.1](/filings/0001213900-25-076767.md) | not reported | [7.9](/filings/0001628280-26-066538.md) | [10.6](/filings/0001213900-26-056270.md) | [13.2](/filings/0001628280-26-066538.md) |
| Short-term borrowings | $m | [11.2](/filings/0001628280-23-039641.md) | [6.7](/filings/0001213900-25-032213.md) | [0.8](/filings/0001628280-24-024396.md) | [2.5](/filings/0001628280-24-037277.md) | [2.6](/filings/0001628280-24-047969.md) | [2.7](/filings/0001213900-26-043785.md) | not reported | not reported | not reported | [7.9](/filings/0001213900-26-056270.md) | [10.6](/filings/0001213900-26-056270.md) | not reported |
| Shareholders' equity | $m | [(14.3)](/filings/0001628280-24-047969.md) | [(31.6)](/filings/0001213900-25-112615.md) | [13.7](/filings/0001213900-25-112615.md) | [10.6](/filings/0001213900-25-112615.md) | [6.9](/filings/0001213900-25-112615.md) | [6.6](/filings/0001213900-26-043785.md) | [13.9](/filings/0001213900-25-112615.md) | [12.4](/filings/0001213900-25-112615.md) | [10.5](/filings/0001213900-25-112615.md) | [17.7](/filings/0001628280-26-066538.md) | [(26.6)](/filings/0001213900-26-056270.md) | [(25.6)](/filings/0001628280-26-066538.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(1.4) d](/filings/0001628280-24-047969.md) | [(1.2) d](/filings/0001213900-25-032213.md) | [(2.6)](/filings/0001213900-25-045396.md) | [(5.6) d](/filings/0001213900-25-076767.md) | [(6.1) d](/filings/0001213900-25-112615.md) | [(8.0) d](/filings/0001213900-26-043785.md) | [(15.2)](/filings/0001213900-26-056270.md) | [(6.7) d](/filings/0001628280-26-066538.md) | [(8.4) d](/filings/0001213900-25-112615.md) | [(6.3) d](/filings/0001213900-26-043785.md) | [(10.5)](/filings/0001213900-26-056270.md) | [(10.6) d](/filings/0001628280-26-066538.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001628280-24-047969.md) | [0.0 d](/filings/0001213900-25-032213.md) | [0.0](/filings/0001213900-25-045396.md) | [0.0 d](/filings/0001213900-25-076767.md) | [0.0 d](/filings/0001213900-25-112615.md) | [0.0 d](/filings/0001213900-26-043785.md) | [0.0](/filings/0001213900-26-056270.md) | [0.1 d](/filings/0001628280-26-066538.md) | [0.0 d](/filings/0001213900-25-112615.md) | [0.1 d](/filings/0001213900-26-043785.md) | [0.1](/filings/0001213900-26-056270.md) | [0.0 d](/filings/0001628280-26-066538.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2.2](/filings/0001628280-23-039641.md) | [3.8](/filings/0001628280-24-024396.md) | [3.9](/filings/0001628280-24-037277.md) | [4.1](/filings/0001628280-24-047969.md) | [0.0](/filings/0001213900-25-045396.md) | [0.1](/filings/0001213900-25-076767.md) | [0.1](/filings/0001213900-25-112615.md) | [3.4](/filings/0001213900-26-056270.md) | [7.1](/filings/0001628280-26-066538.md) | [22.1](/filings/0001213900-25-112615.md) | [35.3](/filings/0001213900-26-056270.md) | [38.5](/filings/0001628280-26-066538.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 38,477,789 at 2026-10-20, from the cover of the [10-Q filed 2026-10-20](/filings/0001628280-26-066538.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.